Gosset Activin receptor type-2B Overview
Activin receptor type-2B (ACVR2B) is a transmembrane serine/threonine kinase receptor that is part of the transforming growth factor-beta (TGF-β) superfamily. It serves as a type II receptor for multiple dimeric ligands, including activins, myostatin (GDF8), and GDF11, all of which are critical regulators of muscle growth, cell differentiation, and development[1][2][3]. When a ligand binds, ACVR2B forms a complex with a type I receptor, leading to phosphorylation and activation of the type I receptor, which then initiates intracellular SMAD signaling[2][3][4]. In muscle, ACVR2B is the primary receptor for myostatin, a key negative regulator of muscle mass, making it an attractive therapeutic target for conditions characterized by muscle atrophy or wasting[1][3]. Drugs such as bimagrumab bind to the ligand-binding domain of ACVR2B, blocking ligand interaction and preventing downstream signaling, thus promoting muscle growth and repair[7]. ACVR2B is also implicated in cancer, fibrosis, and fertility regulation, due to its broader role in cell proliferation and differentiation[2][5]. Safety concerns primarily relate to the potential impact of broad TGF-β pathway inhibition, which can disturb normal growth, reproductive, and endocrine processes[2].
Mechanism of Action
Competitive inhibition of ligand (myostatin/activin/GDF11) binding; Blocking downstream SMAD signaling
Biological Functions
Disease Associations
Safety Considerations
- Potential off-target inhibition of related TGF-β family signaling
- Impact on reproductive and endocrine function
Interacting Drugs
Associated Biomarkers
| Biomarker |
|---|
| Circulating myostatin/activin A levels (for pathway inhibition) |
| Muscle mass (for efficacy monitoring in muscle-wasting diseases) |